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ABSTRACT
The orphan G protein-coupled receptor GPR55 has been directly or indirectly 
related to basic alterations that drive malignant growth: uncontrolled cancer cell 
proliferation, sustained angiogenesis, and cancer cell adhesion and migration. 
However, little is known about the involvement of this receptor in metastasis. 
Here, we show that elevated GPR55 expression in human tumors is associated with 
the aggressive basal/triple-negative breast cancer population, higher probability 
to develop metastases, and therefore poor patient prognosis. Activation of GPR55 
by its proposed endogenous ligand lysophosphatidylinositol confers pro-invasive 
features on breast cancer cells both in vitro and in vivo. Specifically, this effect is 
elicited by coupling to Gq/11 heterotrimeric proteins and the subsequent activation, 
through ERK, of the transcription factor ETV4/PEA3. Together, these data show that 
GPR55 promotes breast cancer metastasis, and supports the notion that this orphan 
receptor may constitute a new therapeutic target and potential biomarker in the 
highly aggressive triple-negative subtype.
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INTRODUCTION
G protein-coupled receptors (GPCRs), the largest 
superfamily of receptors, are involved in a wide variety of 
biological functions [1], and their dysfunction contributes 
to many human diseases [2]. Increasing evidence indicates 
that aberrant GPCR signaling is implicated in cancer 
initiation and progression [3–5], and therefore the search 
for new GPCRs involved in these processes has become 
a strategy for the development of new cancer treatments. 
GPR55 is a GPCR that is engaged by lipids, specifically 
lysophosphatidylinositol (LPI) and certain cannabinoid 
compounds [6–8]. However, due to the lack of proof for 
in vivo activation by these ligands, this receptor remains 
in the Class A orphan subfamily [9]. Increasing evidence 
supports that GPR55 is an important component of the 
molecular circuitry that controls cancer cell behavior. 
Thus, this receptor has been shown to drive cancer 
cell proliferation in in vitro and/or in vivo models of 
glioblastoma [10]; prostate [11], ovarian [11] and skin 
carcinoma [12]; melanoma [13], and non-small lung cancer 
[14]. GPR55 has also been indirectly associated to both pro-
angiogenic responses [15] and to pro-migratory phenotypes 
in breast [16] and colon cancer cells [17]. However, 
little is known about the real impact of these effects on 
the metastatic process, the final and most lethal stage of 
cancer progression, as well as the molecular mechanisms 
governing those actions. Hence, here we aimed at shedding 
light on these two particular issues by focusing on breast 
cancer, one of the leading causes of death in women [18].
RESULTS 
GPR55 expression correlates with triple-negative 
tumors and poor patient prognosis 
To understand the role of GPR55 in the advanced 
stages of breast cancer progression, we first investigated 
whether there was an association between GPR55 levels 
and patient prognosis. We analyzed GPR55 protein 
expression in a tissue microarray (TMA) containing 483 
breast human samples [19]. We found a strong correlation 
between high GPR55 expression and reduced disease-free 
survival (Figure 1A). To determine whether this association 
was also observed at the mRNA level, we analyzed the 
publically available TCGA microarray data set that 
contains molecular and clinical data from 825 breast 
cancer patients [20]. Women with high tumor GPR55 
mRNA expression presented reduced overall survival than 
those with low GPR55 mRNA levels (Figure 1B). In an 
additional dataset containing 295 breast cancer samples 
[21], high GPR55 mRNA expression was associated with 
reduced metastasis-free survival (Figure 1C). Since breast 
cancer is a very heterogeneous disease, we studied whether 
GPR55 expression was associated to a specific molecular 
subtype. We found a strong association between GPR55 
protein levels and triple-negative tumors (Figure 1D). 
Specifically, moderate or high GPR55 staining was found 
in 82% of them (Figure 1D). Likewise, GPR55 mRNA 
levels were elevated in basal tumors with respect to the 
other molecular subtypes of breast cancer (i.e. normal-
like, luminal A or B, and HER2-enriched) in two datasets 
containing a total of 2557 human samples [20, 22] 
(Figures 1E and 1F), and in basal human breast cancer 
cell lines with respect to cell lines with other molecular 
features (Figure 1G). Together, these findings show that an 
elevated GPR55 expression is associated with the highly 
aggressive basal/triple-negative breast cancer subtype, 
higher probability to develop metastases, and therefore 
poor patient prognosis. 
GPR55 bestows pro-metastatic advantages to 
breast cancer cells in vitro and in vivo
As high tumor aggressiveness is intimately related 
to the capability of cancer cell dissemination and the 
establishment of metastatic lesions, we next analyzed 
whether GPR55 bestows pro-metastatic properties to 
triple-negative breast cancer cells. First, we studied the 
role of GPR55 in cancer cell invasion, a pivotal event 
involved in the generation of metastases [23]. Triple-
negative MDA-MB-231 breast cancer cells increased their 
invasive behavior when either FBS (Figure 2A) or LPI 
(Figure 2B) was used as chemoattractant. This effect was 
markedly reduced when GPR55 expression was knocked-
down (Figures 2A–2C), and rescued upon GPR55 ectopic 
overexpression (Figures 2D–2F). The role of LPI as a 
positive directional cue for GPR55 expressing cells was 
substantiated by directional migration experiments. Thus, 
the migration towards LPI observed in MDA-MB-231 
cells (Forward Migration Index = 0.117) was abolished by 
GPR55 knockdown (Forward Migration Index = –0.025, 
Figure 2G). Similar effects were observed in an animal 
model of lung metastasis. Mice injected with MDA-
MB-231 cells expressing endogenous levels of GPR55 
bore significantly more metastases when treated with 
LPI than when treated with vehicle (Figures 2H and 2I). 
Injection into the circulation of MDA-MB-231 cells with 
reduced GPR55 expression generated significantly less 
lung metastases than injection of control cells, and, in this 
case, LPI did not increase the number of metastatic lesions 
(Figures 2H and 2I). Moreover, the number of metastases 
augmented when the injected cells overexpressed GPR55 
(Figures 2H and 2I). These observations show that 
activation of GPR55 bestows pro-metastatic features to 
breast cancer cells both in vitro and in vivo. 
GPR55-driven pro-invasive responses involve 
coupling to Gq/11 and activation of RhoA
The molecular mechanisms responsible for GPR55-
driven pro-metastatic properties were then studied. First, 
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Figure 1: GPR55 expression correlates with triple-negative tumors and poor patient prognosis. (A–C) Kaplan-Meier 
curves for disease-free survival (A), overall survival (B), and metastasis-free survival (C). Data plotted in A correspond to the human breast 
tumor tissues with complete clinical information contained in the 483-sample tissue microarray generated at the University Hospital of 
Kiel and described in [19]. Cases were scored as 0 (no staining), 1 (weak staining), 2 (moderate staining), or 3 (high staining), for GPR55 
expression. A representative image of each category is shown in (D) upper panel. Scale bar, 0.25 mm. Samples scoring 0 were grouped as 
“low GPR55 expression”, and cases scoring 1-3 as “high GPR55 expression”. Data plotted in (B and C) were obtained from the microarray 
data sets published by the TCGA network in [20] (B), and from the microarray data set published in [21] (C). In these two panels, samples 
were ranked by GPR55 mRNA expression, and the best cutoff was manually selected. Survival curves were statistically compared by the 
log-rank test. (D) Association between GPR55 expression (as determined by staining scoring) and the molecular features of the breast tumor 
samples included in the TMAs described in (A). The Pearson’s chi-squared test was used for statistical analysis. (E–G) Relative GPR55 
mRNA expression in the indicated breast cancer subtypes (E and F) or human breast cancer cell lines (G). Data in (E and F) were obtained 
from the same database as in (B) (for E), and from database in [22] (in F). **p < 0.01 vs. the rest of the subgroups [except Normal-like in 
(E)], and vs. MDA-MB-231 cells in (G).  
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Figure 2: GPR55 confers pro-metastatic advantages on breast cancer cells in vitro and in vivo. (A–F) Cell invasion assays 
were performed with four different cell lines: MDA-MB-231 cells stably expressing a shRNA selectively targeting GPR55 (shGPR55) or 
a non-targeted shRNA (shC) (A–C), or shGPR55 cells stably expressing a GPR55 overexpression plasmid (shGPR55 + GPR55) or the 
corresponding empty vector (shGPR55 + pcDNA3) (D–F). Results are expressed as invasion fold increase towards 10% FBS or 0.5 µM 
LPI vs. shC (A and B) or shGPR55 + pcDNA3 (D and E) vehicle-treated cells, set at 1. (C and F) Relative GPR55 mRNA expression in 
GPR55 knocked-down (C) and GPR55 overexpressing cells (F). (G) Angular histograms of shC (left panel) and shGPR55 (right panel) cells 
migrating in response to a LPI gradient. (H) Representative images of the lung metastases generated by injection of the indicated luciferase 
expressing cell lines. (I) Quantification of the lung bioluminescence signal. *p < 0.05; **p < 0.01 vs. shC or shGPR55 + pcDNA3 vehicle-
treated cells/animals. #p < 0.05; ##p < 0.01 vs. shC or shGPR55 + pcDNA3 FBS- or LPI-treated cells/animals.
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we analyzed which heterotrimeric G protein GPR55 
activates to mediate its actions. Previous reports had 
shown that this receptor couples to G12/13 [24–29] and Gq/11 
proteins [28] as its other closely related lysophospholipid 
receptors [30]. We therefore focused on these two families 
of G proteins, which are in fact intimately related to the 
regulation of cytoskeleton rearrangement, cell migration 
and invasion, and thus the generation of metastases 
[3–5]. By an antibody-capture [35S]GTPγS scintillation 
proximity assay (SPA) [31], we observed that LPI induced 
the coupling of GPR55 to Gq/11 in MDA-MB-231 cells, 
an effect that was not observed in cells with reduced 
expression of the receptor and that was rescued in GPR55 
overexpressing cells (Figure 3A, left). No coupling to 
G12/13 in response to LPI was observed in any of these cell 
lines (Figure 3A, right). The specific activation of Gq/11 
by GPR55 was further confirmed by the use of different 
chimeric constructs that behave as dominant-negative 
mutants for either Gq/11 or G12/13. In this case, the increased 
invasiveness evoked by LPI in GPR55-overexpressing 
cells was prevented when Gq/11 signaling was blocked by 
using a GFP-GRK2 chimeric construct (Figure 3B). In 
contrast, blockade of G12/13 signaling by means of a GFP-
RGS chimera did not alter LPI-induced GPR55-mediated 
cancer cell invasion (Figure 3B). One of the main targets 
of Gq/11 involved in actin remodeling, cell dynamics and 
metastasis is the Rho family of small GTPases, which 
consists of three subfamilies (Rho, Rac, and Cdc42) 
[5, 32]. GPR55 has been shown to activate Rho GTPases 
in non-cancer contexts [24, 26, 28, 29, 33, 34]. In our 
experimental setting, LPI significantly stimulated RhoA 
activity, and this effect was prevented by GPR55 knock-
down (Figure 3C, left). In contrast, neither Rac1 (Figure 
3C, middle) nor Cdc42 (Figure 3C, right) changed their 
activity upon LPI challenge (Figure 3C). Together, these 
findings support that GPR55 activation elicits pro-invasive 
responses in cancer cells by binding to Gq/11 heterotrimeric 
G proteins and activating RhoA.
GPR55 activates the transcription factor ETV4/
PEA3 through coupling to Gq/11 and stimulation 
of ERK 
To further characterize the downstream molecular 
players responsible for GPR55-driven pro-metastatic 
features, we analyzed the expression of a series of 
metastasis-related genes in response to LPI. By using a 
Human Metastasis PCR Array we found a group of genes 
that were modulated by LPI in GPR55-expressing cells 
(Supplementary Table S1). Among them, we focused 
our interest on those whose increased expression was 
ablated when GPR55 was silenced. One of them was the 
transcription factor ETV4/PEA3 (Figure 4A), which has 
been associated with metastasis in different tumor types 
[35, 36], including breast adenocarcinomas in general 
[37] and triple-negative breast cancers in particular [38]. 
First, we validated the reduction in ETV4 mRNA found 
after GPR55 stable knockdown by silencing the receptor 
transiently in MDA-MB-231 cells and an additional 
triple-negative breast cancer cell line (MDA-MB-468, 
Figure 4B), which ruled out the possibility that reduced 
ETV4 mRNA levels were a consequence of adaptive 
mechanisms to the chronic lack of GPR55 or a cell line-
specific event. ETV4 mRNA expression was enhanced 
by LPI both in cell cultures (Figure 4A) and in the 
lung metastases generated in immunodeficient mice 
(Figure 4C), an effect that was not observed upon GPR55 
knock-down (Figures 4A and 4C). Moreover, the increase 
in cell invasion produced by LPI was abolished by ETV4 
transient knockdown (Figure 4D). In line with our previous 
data pointing to the involvement of Gq/11 in LPI action, the 
increase in ETV4 levels produced by this GPR55 ligand 
was abrogated when Gq/11 signaling was blocked with the 
GFP-GRK2 chimera (Figure 4E). It has been described 
that ETV4 expression is controlled by ERK in esophageal 
cancer [39] and so we found in our triple-negative breast 
cancer setting. Thus, LPI increased ERK phosphorylation 
(i.e. activation) via GPR55 (as demonstrated by the lack 
of such effect in GPR55 silenced cells; Figure 4F), and 
through the coupling to Gq/11 (as demonstrated by the 
blockade of this action by the GFP-GRK2 construct; 
Figure 4G). Importantly, the increase in ETV4 mRNA 
levels induced by LPI was prevented by the inhibition 
of the ERK cascade with the MEK inhibitor U0126 
(Figure 4H). Together, these results support that the 
prometastatic responses induced by GPR55 are mediated 
by the coupling to Gq/11 and the subsequent activation of 
ERK, which in turn controls ETV4 expression.
DISCUSSION
Our results show that activation of GPR55 
promotes metastasis in breast cancer, thus supporting 
that this receptor may be exploited as a new target in 
oncology, specifically in the metastatic disease associated 
to the highly aggressive triple-negative breast cancer. 
Indirect links between GPR55 and metastasis have been 
previously suggested in other cancer types. For example, 
Piñeiro et al. showed that anchorage-independent growth 
(a crucial feature of cancer cells during metastatic 
spreading) of a prostate cancer cell line was inhibited 
by GPR55 downregulation [11]. More recently, Kargl 
et al. have reported that pharmacological and genetic 
blockade of GPR55 impairs migration of a colon cancer 
cell line in vitro and in an animal model of liver metastasis 
[17]. Regarding breast cancer specifically, Ford et al. 
demonstrated that LPI induces migration and elongation 
of MDA-MB-231 cells [16]. However, in the latter study 
it remained unclear whether the LPI effects were mediated 
by GPR55. Ford et al. also observed that the poorly 
metastatic MCF-7 cell line (which expresses low levels 
of GPR55) increases its migration capacity upon GPR55 
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overexpression, an effect that was increased by LPI and 
completely blocked by selective GPR55 knockdown [16]. 
The work presented here cogently shows that activation of 
GPR55 promotes metastatic responses in vitro and in vivo 
in triple-negative breast cancer. These results suggest that 
blockade of this receptor may be a useful strategy for the 
management of the metastatic disease in this population. 
The pharmacology of GPR55 is still quite controversial 
and most compounds with activity on this receptor bind to 
additional targets. It would be therefore desirable to find/
synthesize compounds with blocking activity selectively 
on GPR55 to test their actual therapeutic potential. 
Our findings also show that GPR55 may have not 
only predictive but prognostic value. Thus, an elevated 
GPR55 expression is associated with the basal/triple-
negative breast cancer subtype, higher probability to 
develop metastases, and therefore poor patient prognosis. 
This notion that the LPI/GPR55 axis may represent a new 
marker with prognostic value is supported by additional 
observations. Regarding GPR55 itself, our group has 
previously observed that this receptor is upregulated 
in human skin tumors and other human squamous cell 
carcinomas compared with the corresponding healthy 
tissues [19], and that high GPR55 expression correlates 
with high histological grade in breast, pancreas and brain 
tumors, as well as with decreased overall survival in 
glioblastoma patients [10]. Additionally, increased levels 
of the proposed endogenous GPR55 ligand LPI [40], have 
been found in plasma and/or ascites from patients with 
colon [17] or ovarian cancer [41, 42], when compared 
with healthy subjects, or with women with non-cancerous 
pathologies. It would be very interesting to conduct similar 
studies in larger cohorts of breast cancer patients, which 
should include samples from the different molecular 
subtypes, to determine whether the association between 
GPR55 expression and poor prognosis in triple-negative 
cases that we report here occurs concomitant with elevated 
LPI plasma levels.
Figure 3: GPR55-driven pro-invasive responses involve coupling to Gq/11 and activation of RhoA. (A) Activation of Gq/11 or 
G12/13 proteins by LPI (10
-5 M) as determined by Antibody-capture [35S]GTPγS scintillation proximity assay (SPA). Results are expressed as 
percentage of [35S]GTPγS basal binding (BB, binding obtained in the absence of the agonist, set as 100% for each cell line, and represented 
as a single bar in the graphs) to the indicated subunit. (B) Invasion of shGPR55 + GPR55 cells after incubation with 0.5 µM LPI or the 
corresponding vehicle (PBS) for 24 h, in the presence of a construct blocking Gq/11 (GRK2) or G12/13 signaling (RGS), or the corresponding 
empty vector (GFP). (C) Activation of the indicated small GTPases after a 3 min incubation with 0.5 µM LPI. Results are expressed as fold 
increase activation over the corresponding vehicle-treated cells, set at 1. *p < 0.05; **p < 0.01 vs. vehicle-treated cells. ##p < 0.01 vs. GFP 
LPI-treated cells. #p < 0.01 vs. LPI-treated cells.
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Figure 4: GPR55 activates the transcription factor ETV4/PEA3 through coupling to Gq/11 and stimulation of ERK. 
Relative ETV4 mRNA expression in the indicated cell lines (A and B), in the metastases derived from those cell lines (C) (see Figure 2G–2H 
for details on metastasis generation and treatment), and in shC cells transfected with constructs blocking blocking Gq/11 (GRK2) or G12/13 
signaling (RGS), or the corresponding empty vector (GFP) (E). In A, ETV4 expression was determined by the RT2 Profiler PCR Array of 
Human Tumor Metastases (see Supplementary Table S1 legend), and in (B), (C and E) by real-time quantitative PCR. In (B), siGPR55 1 
and 2 represent two different GPR55 siRNAs. (D) Invasion of the indicated cell lines upon transient ETV4 knockdown. (F and G) Western 
blot analysis of phospho-ERK in shC and shGPR55 cells after treatment with 0.5 µM LPI or the corresponding vehicle (PBS) for 3 min 
(F) and shC cells after incubation with LPI and expressing the indicated G protein signaling blocking constructs (G). Representative 
luminograms are shown. Numbers on top of the images correspond to the densitometric analysis of pERK levels and are expressed as fold 
increase vs. the corresponding vehicle-treated cells, set at 1 (n = 3). (H) Relative ETV4 mRNA expression, as determined by real-time 
quantitative PCR, in shC cells challenged with 0.5 µM LPI and the MEK inhibitor U0126 (1µM) for 3 min. **p < 0.01 vs. siC or shC 
vehicle-treated cells. ##p < 0.01 vs. siC or shC LPI-treated cells (C), GFP LPI-treated cells (E) or LPI-treated cells (H). 
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MATERIALS AND METHODS
Ethics statement
Investigation has been conducted in accordance 
with the ethical standards and according to the Declaration 
of Helsinki, and according to national and international 
guidelines, and has been approved by the authors’ 
institutional review board.
Tissue microarrays (TMAs)
PFA-fixed and paraffin-embedded blocks of tumor 
tissue from cases operated in the University Hospitals 
of Kiel between 1997 and 2010 were used for TMA 
construction. All patients gave informed consent, and the 
study was authorized by the Hospital’s Ethics Committee. 
TMAs were generated by punching two 1 mm spots of 
each patient’s sample. This resulted in a series of 483 
tumor samples. Complete histopathological information 
was available for all the patients, including date and cause 
of death as well as date of local and/or distant relapse.
Immunohistological analysis
Tissue sections were subjected to a heat-induced 
antigen retrieval step prior to exposure to an anti-GPR55 
antibody (Abcam, Cambridge, UK). Immunodetection was 
performed using the Envision method with DAB as the 
chromogen. For GPR55 expression, cases were scored as 
0 (no staining), 1 (weak staining), 2 (moderate staining), 
or 3 (high staining). Anti-GPR55 antibody specificity 
controls have been previously reported [12].
Real-time quantitative PCR, and analysis of 
published microarray datasets
RNA was isolated with Trizol Reagent (Invitrogen, 
Barcelona, Spain) with the Real Star Kit (Durviz, Valencia, 
Spain), and cDNA was obtained with Transcriptor Reverse 
Transcriptase (Roche Applied Science, Barcelona, Spain). 
The primers used for GPR55 amplification were: sense 
5ʹ-CATGTGTTTCTCCAACGTCAA-3ʹ and antisense 
5ʹ-TGCGGAATTCTTTGATGACA-3ʹ; and for ETV4 
amplification: sense 5ʹ-GCAGTTTGTTCCTGATTTCCA- 3ʹ 
and antisense 5ʹ-ACTCTGGGGCTCCTTCTTG-3ʹ. Probes 
were from the Universal Probe Library (Roche Applied 
Science), and TATA Binding Protein (TBP) was used as 
reference: sense 5ʹ-CCCATGACTCCCATGACC-3ʹ and 
antisense 5ʹ-TTTACAACCAAGATTCACTGTGG-3ʹ). 
Human GPR55 mRNA expression was obtained 
from the microarray dataset published by the TCGA 
network in [20], downloaded from the cBio Cancer 
Genomics Portal [43]; from the microarray data set 
published in [21], downloaded from the Stanford 
Microarray Database (http://microarray-pubs.stanford.
edu/wound_NKI/explore.html); and from database in 
[22], obtained through the European Genome-Phenome 
Archive (http://www.ebi.ac.uk/ega/) (accession number 
EGAS00000000083).
Cell cultures
All the human breast adenocarcinoma cell lines were 
from ATCC-LGC (Barcelona, Spain). To stably knockdown 
GPR55 in MDA-MB-231 cells, a target-specific shRNA 
construct was used (GeneCopoeia, Rockville, MD). 
A scrambled shRNA construct was used as control 
(GeneCopoeia). Stably transfected cells were selected 
with puromycin. Transient GPR55 and ETV4 knockdown 
were carried out by using different ON-TARGETplus 
siRNAs (Dharmacon, Lafayette, CO): GPR55 siRNA1: 
5ʹ-GAAUUCCGCAUGAACAUCA-3ʹ; GPR55 siRNA2: 
5ʹ-GAGAAACAGCUUUAUCGUA- 3ʹ; for ETV4 a 
SMARTpool consisting of 4 different siRNAs was 
used: 5ʹ-GGGCAGAGCAACGGAAUUU-3ʹ, 5ʹ-GAAU 
GGAGUUCAAGCUCAU-3ʹ, 5ʹ-GGACUUCGCCUAC 
GACUCA-3ʹ and 5ʹ-GAUGAAAGCCGGAUACUUG- 3ʹ. 
A non-targeted siRNA was used as control: 5ʹ-UUCU 
CCGAACGUGUCACGUtt-3ʹ. For the generation of 
MDA-MB-231 cells overexpressing GPR55, a 3xHA-
GPR55 plasmid, or the corresponding empty vector 
(pcDNA3, Invitrogen) were used. All transfections were 
performed with Lipofectamine 2000 (Invitrogen). The 
graphs showing the resulting GPR55 or ETV4 mRNA 
levels are shown in Supplementary Figure S1. All cell lines 
were maintained in DMEM supplemented with 10% FBS. 
The chimeric constructs to block Gq/11 or G12/13 
signaling were generated by fusion of a GFP containing 
pCEFL plasmid to the RGS domain of GRK2 (GFP-
GRK2) or to the RGS domain of PDZ-RhoGFP (GFP-
RGS) [44]. 
Cell invasion
Cell invasion assays were performed in BD BioCoatTM 
MatrigelTM Invasion Chambers (BD Biosciences, Bedford, 
MA). Transwell inserts were placed onto 24-well, glass 
bottom greiner multiwell plates. Chemoattractants (10% FBS 
or 0.5 mM LPI) were added into the wells, and serum starved 
cells were placed into the inserts. After 24 h incubation, cells 
were fixed in 4% formaldehyde and stained with DAPI 
(Roche Pharma, Madrid, Spain). Images were taken with 
a confocal microscope (Leica TCS SP5) using a 20X DRY 
0.7 NA objective. Capturing conditions were set up in two 
independent channels for DAPI stained cells and insert 
membrane reflection. Four equidistant non-overlapping fields 
were acquired close to the center of each insert avoiding 
possible influences from borders. For each field a volume 
big enough to contain all (migrating and non-migrating) cells 
was captured with a Z distance between images of 1 micron 
(small enough relative to nuclei size to make sure no nuclei 
was left unnoticed). All stack fields were visualized using 
Imaris x64 7.3.1 software. The center of every cell was 
recorded relative to the transwell insert membrane and cells 
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were classified as either migrating or non migrating cells. 
Cells in touch with image borders were discarded.
Chemotaxis assays
2D chemotaxis μ-slide chambers (Ibidi, Munich, 
Germany) were precoated with collagen and cells where 
allowed to adhere and serum starve overnight. Incomplete 
media alone or supplemented with LPI (1 µM) were 
located in the reservoir chambers. Cell migration was 
imaged by time lapse microscopy (IX83 inverted 
microscope, Olympus; 20x magnification) at 5 minutes 
intervals over a period of up to 20 hours. Image J Manual 
Tracking plug-in and Chemotaxis Migration tool (Ibidi) 
were used to quantify the cell trajectories.
Generation of lung metastases
Lung metastases were generated by injection of the 
different luciferase expressing cell lines (5 × 105) into the 
lateral tail vein of 6 week-old NOD/SCID female mice. 
Starting from day 2 after cell injection, half of the animals 
of each experimental group received LPI treatment (12 µg, 
i.p., three times per week) and the other half treatment with 
the corresponding vehicle (PBS). Forty five days after cell 
injection, animals were analyzed by bioluminescence after an 
intraperitoneal injection of D-Luciferin (Sigma) in an IVIS 
2000 system (Xenogen Corp, Alameda, CA). Imaging data 
were processed with Living Image software (Xenogen Corp).
Antibody-capture [35S]GTPγS scintillation 
proximity assay (SPA)
SPAs were performed as previously described [45]. 
Briefly, cell membrane homogenates were incubated in 96-
well Isoplates (Perkin Elmer Life Sciences, Maanstraat, 
Germany) in incubation buffer containing 0.4 nM [35S]
GTP
γ
S (Perkin Elmer) and 50 or 100 µM GDP for Gq/11 or 
G12/13 proteins, respectively. Specific antibodies for each Gα 
subunit (rabbit polyclonal anti-G
αq/11
 and rabbit polyclonal 
anti-G
α12/13
; Santa Cruz Biotechnologies, Madrid, Spain) 
and PVT SPA beads coated with protein A (Perkin Elmer) 
were used. Radioactivity was quantified on a MicroBeta 
TriLux scintillation counter (Perkin Elmer).
Activity of Rho family GTPases
The activity of the Rho family of small GTPases 
was determined by RhoA/Rac1/Cdc42 Activation Assay 
Combo Biochem Kit™ (Cytoskeleton, Denver, CO) 
following manufacturer’s instructions.
Human metastasis PCR array
The expression of metastasis related genes after 
treatment with LPI (0, 5 µM, 20 h) or the corresponding 
vehicle (PBS) was determined by the RT2 Profiler PCR 
Array of Human Tumor Metastases (ref.  524 PAHS-
028Z-4, Qiagen, Valencia, CA). RNA from cell cultures 
was isolated with Trizol reagent (Sigma, St. Louis, MO), 
including a DNA digestion step with genomic DNA 
elimination mix (Qiagen). cDNA was subsequently 
obtained with a RT2 first strand kit according to 
manufacturer’s instructions (Qiagen). Real-time PCR 
assay was performed using the RT2 profiler PCR array in 
combination with RT2 SYBR Green master mix (Qiagen). 
Amplifications were run in a 7900 HT-fast real-time PCR 
system (Applied Biosystems, Carlsbard, CA), and data 
were analyzed using the SABiosciences PCR array data 
analysis template Excel (Qiagen).
Western blot analysis
Lysates from the different cell lines or lungs were 
obtained, and proteins were separated by SDS–PAGE 
and then transferred onto PVDF membranes. Blots were 
incubated with anti-phospho-ERK (Thr202/Tyr204), 
anti-ERK (Cell Signaling Technology, Danvers, MA, 
USA) and anti-α-Tubulin (TUB) (used as loading control, 
Sigma-Aldrich). Luminograms were obtained with the 
Amersham Enhanced Chemiluminescence Detection Kit 
(GE Healthcare, Uppsala, Sweden), and densitometric 
analysis was performed with Quantity One software (Bio-
Rad, Madrid, Spain). 
Statistical analysis
The Pearson’s chi-squared test was used for the 
analysis of the association between GPR55 expression 
and the molecular features of the breast tumor samples 
included in the TMA. Kaplan-Meier survival curves 
were statistically compared by the log-rank test. Analysis 
of variance (ANOVA) with a post hoc analysis by the 
Student-Newman-Keuls’ test was routinely used for the 
rest of the analyses. 
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